Brief: Ocumension Therapeutics Says Revenue Increased 55.0% For Year To RMB246.4 Mln
21/03/2024 15:02
March 21 (Reuters) - Ocumension Therapeutics 1477.HK :
* REVENUE INCREASED 55.0% FOR YEAR TO RMB246.4 MILLION
* FY LOSS RMB379.8 MILLION VERSUS LOSS RMB402.6 MILLION
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application